{"id":2760,"date":"2023-11-09T09:52:23","date_gmt":"2023-11-09T08:52:23","guid":{"rendered":"https:\/\/corlife.eu\/?p=2760"},"modified":"2026-02-10T18:02:26","modified_gmt":"2026-02-10T17:02:26","slug":"02-23-eacts-annual-meeting-2023-update","status":"publish","type":"post","link":"https:\/\/corlife.eu\/en\/2023\/11\/09\/02-23-eacts-annual-meeting-2023-update\/","title":{"rendered":"Newsletter 02\/23: EACTS Annual Meeting 2023, Update"},"content":{"rendered":"

02\/2023<\/p>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n

At the annual meeting of the EACTS in Vienna, recent clinical data of cell-free aortic and pulmonary valves were presented and discussed in three lectures. After more than 1,000 implantations, orthotopically implanted cell-free allografts have become established as reasonable alternatives for heart valve replacement. We have linked the original articles for you and summarized the key statements synoptically as tables in our Newsletter-2023-02<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>

<\/div><\/div><\/div><\/div><\/div>
\n